Compare MS & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MS | NVS |
|---|---|---|
| Founded | 1924 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.4B | 254.8B |
| IPO Year | N/A | 1991 |
| Metric | MS | NVS |
|---|---|---|
| Price | $174.67 | $132.33 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 15 | 3 |
| Target Price | ★ $167.38 | $118.00 |
| AVG Volume (30 Days) | ★ 5.5M | 1.6M |
| Earning Date | 01-15-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.29% | 1.96% |
| EPS Growth | ★ 48.48 | N/A |
| EPS | ★ 9.75 | 7.30 |
| Revenue | ★ $68,532,000,000.00 | $56,372,000,000.00 |
| Revenue This Year | $17.60 | $9.33 |
| Revenue Next Year | $5.64 | $2.75 |
| P/E Ratio | ★ $17.94 | $18.14 |
| Revenue Growth | ★ 17.59 | 12.88 |
| 52 Week Low | $94.33 | $96.06 |
| 52 Week High | $176.00 | $134.24 |
| Indicator | MS | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 57.93 |
| Support Level | $168.10 | $128.91 |
| Resistance Level | $170.27 | $134.24 |
| Average True Range (ATR) | 4.14 | 1.77 |
| MACD | 1.06 | 0.47 |
| Stochastic Oscillator | 94.58 | 82.41 |
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 80,000 employees as of year-end 2024. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $7.9 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the great financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with nearly $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.